Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma after other treatments have failed. It is taken by mouth. It is a PI3 kinase inhibitor. Duvelisib is a small molecule, orally bioavailable inhibitor with preferential activity against PI3K-delta and PI3K-gamma isoforms, producing inhibition of downstream AKT signaling, reduction in malignant B cell survival, and modulation of the tumor microenvironment. The recommended oral dosing regimen for adults in approved indications is 25 mg twice daily, with hepatic metabolism primarily via CYP3A4 and a terminal half-life in the range of several hours, necessitating caution with strong CYP3A modulators. Clinically important toxicities include increased risk of severe infections, immune-mediated colitis and diarrhea, pneumonitis, and cutaneous reactions, so monitoring of blood counts, liver tests, and signs of infection is required during treatment.
Quality control specifications for duvelisib active pharmaceutical ingredient typically monitor a set of specified related substances and unspecified impurities by validated chromatographic methods; common practice in registered specifications sets reporting thresholds and limits such as individual unspecified impurities at or below 0.10 percent by area, specified related compounds in the range of 0.1 to 0.5 percent depending on the impurity and toxicological assessment, and a total impurity limit commonly not exceeding about 1.0 percent to 2.0 percent by area. Analytical testing also includes residual solvents control per ICH Q3C, elemental impurities per ICH Q3D, water content and assay for potency, and targeted monitoring of likely process- and degradation-related compounds such as desmethyl derivatives, N-oxide or oxidative products, dealkylated species, and hydrolytic breakdown products; final specification limits should be established based on stability data and regulatory guidance.
Duvelisib is approved for oral treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, and for follicular lymphoma in patients who have received at least two prior systemic therapies; it is used when prior lines of therapy have failed or the disease has relapsed.
Duvelisib inhibits class I PI3 kinase isoforms, with preferential activity against PI3K-delta and PI3K-gamma, blocking PI3K-mediated phosphorylation of PIP2 to PIP3, reducing AKT pathway signaling, impairing malignant B cell proliferation and survival, and altering the immune and stromal support in the tumor microenvironment.
Yes, duvelisib, marketed as Copiktra, is FDA approved for specific relapsed or refractory B cell malignancies as described in the prescribing information; approval is for use under defined indications with recommended dosing and monitoring requirements.
Idelalisib is an orally active small molecule that selectively inhibits the PI3K-delta isoform; its function is to block PI3K-delta signaling in malignant B cells, leading to reduced proliferation and survival, and it is used clinically in certain B cell malignancies with safety and monitoring considerations that are distinct from dual isoform inhibitors such as duvelisib.
